TTY Biopharm 4105

H1/2026 Operational Results Report

Investor Relations Report 2026.09.16

Disclaimer

This presentation contains certain forward-looking statements.

These forward-looking statements may be identified by words such as ‘believes’, ‘expects’, ‘anticipates’, ‘projects’, ‘intends’, ‘should’, ‘seeks’, ‘estimates’, ‘future’ or similar expressions or by discussion of, among other things, strategy, goals, plans or intentions. Various factors may cause actual results to differ materially in the future from those reflected in forward-looking statements contained in this presentation, among others:

1 pricing and product initiatives of competitors;
2 legislative and regulatory developments and economic conditions;
3 delay or inability in obtaining regulatory approvals or bringing products to market;
4 fluctuations in currency exchange rates and general financial market conditions;
5 uncertainties in the discovery, development or marketing of new products or new uses of existing products, including without limitation negative results of clinical trials or research projects, unexpected side-effects of pipeline or marketed products;
6 increased government pricing pressures;
7 interruptions in production
8 loss of or inability to obtain adequate protection for intellectual property rights;
9 litigation;
10 loss of key executives or other employees; and
11 adverse publicity and news coverage.

TTY Biopharm cautions that this foregoing list of factors is not exhaustive. There may also be other risks that management is unable to predict at this time that may cause actual results to differ materially from those in forward-looking statements. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date on which they are made. TTY Biopharm undertakes no obligation to update publicly or revise any forward-looking statements. Any statements regarding earnings growth is not a profit forecast and should not be interpreted to mean that TTY Biopharm’s earnings or earnings per share for this year or any subsequent period will necessarily match or exceed published earnings or earnings per share forecasts of TTY Biopharm Company Limited.

TTY BIOPHARM 台灣東洋藥品

01 H1/2026 Operational Highlights

- Revenue Performance
- Key Product Achievements

台灣東洋藥品

Operational Results Report

Revenue Performance

Revenue, operating profit, and EPS of H1/2026 hit five-year highs.

Record High

Consolidated Revenue

YoY +6.8%、NT$3,172 million

Record High

Consolidated Operating Profit

YoY +19.3%、NT$977 million

Record High

EPS

YoY +25.7%、NT$3.42



2026 Key Product Achievements

普肺康®
Pulmivex®
Aumolertinib 55 mg

Drug Ingredient: Aumolertinib
Drug Classification: 3rd-Generation EGFR-TKI Oral Targeted Therapy
Manufacturing Site: TTY's Lioudu Plant

2026. 08 .01 Officially covered by National Health Insurance

2026 Key Product Achievements

01 First Domestically Manufactured Drug

As Taiwan's first 3rd-generation EGFR-TKI oral targeted drug for lung cancer self-developed by a local pharmaceutical company, TTY, it represents a major milestone in "domestic drug manufacturing" and breaks the past reliance on international imports for 3rd-generation lung cancer targeted therapies.

02 Benefiting Patients

In the past, 3rd-generation targeted therapies for advanced non-small-cell lung cancer (NSCLC) heavily relied on international imports. Domestic production effectively mitigates the risks associated with international supply chain uncertainties, and significantly enhances medical resilience and drug accessibility.

普肺康®
Pulmivex®
Aumolertinib 55 mg

03 Deepening Local Presence

- Establish an integrated production line to centralize manufacturing at the Lioudu Plant.
- Position the plant as TTY's flagship manufacturing base for cancer targeted therapies, alongside liposomal antibiotics.

04 Expected Targets

Complete hospital formulary inclusion across medical centers within one year.

Launch 4 clinical trials in Taiwan with a total of 400 participants.

Operational Results Report

2026 Key Product Achievements

- **September Delivery:** On time with zero delays.
- **October Vaccination Campaign:** Launch of public/self-paid cell-based and adjuvanted flu vaccines.

FLUAD®
輔流禦流感疫苗

Adjuvanted trivalent flu vaccine

Country of Manufacture: United Kingdom
Target Audience: Adults aged 50 and older
Additional Information: Available for both government-funded and self-paid vaccination (120,000 doses are provided under the government-funded program).

FLUCELVAX®
輔流威護流感疫苗

Cell-based flu vaccine

Country of Manufacture: Germany
Target Audience: Children aged 6 months and older, and adults
Additional Information: Available for both government-funded and self-paid vaccination (650,000 doses are provided under the government-funded program).

台灣東洋藥品

Operational Results Report

02 H1/2026 Financial Performance

TTY BIOPHARM 台灣東洋藥品

H1/2026 Financial Performance

Income Statement (Unit: NT$ Thousands)	2026 H1	2025 H1	YoY Differences	YoY %
Operating Revenue	**3,172,151**	**2,970,900**	201,251	**6.8%**
Operating Cost	1,290,772	1,200,754	90,018	7.5%
Gross Profit	**1,881,379**	**1,770,146**	**111,233**	**6.3%**
Gross Margin (%)	59.3%	59.6%		
Operating Expenses	904,845	951,586	-46,741	-4.9%
Operating Profit	**976,534**	**818,560**	**157,974**	**19.3%**
Operating Margin (%)	30.8%	27.6%		
Non-operating Income	141,121	90,667	50,454	55.6%
Profit before Tax	1,117,655	909,227	208,428	22.9%
Net Income	**897,622**	**709,719**	**187,903**	**26.5%**
Net Margin (%)	28.3%	23.9%		
Net Profit Attributable to Owners of the Parent Company	849,483	675,752	173,731	25.7%
EPS (Unit: NT$)	3.42	2.72		

Analysis

- Operating revenue YoY **+6.8%** is due to the growth of Oncology BU's revenue compared to H1/2025 revenue.
- Gross margin **59.3%** is close to H1/2025.
- Operating Expenses YOY -4.9% is due to our strategies focused on both cost reduction and efficiency improvement.
- Non-operating income YOY **+55.6%** is mainly due to the impact of foreign exchange fluctuations.
- Based on the above, net income after tax is NT$898 million, the net profit attributable to owners of the parent company is NT$849 million, and EPS is NT$3.42 which represents YoY +NT$0.7.

03 2026 Outlook

2026 Outlook

- Comprehensive Product Line Covering In-House R&D, In-Licensing, and International Collaborations



- Unless otherwise specified, regions refer to Taiwan.

2026 Three Strategies Driving TTY's International Expansion

Export
Complex Generics

Global Submission Plan of Lipo-AB

- Maintaining stable shipments to US.
- Obtaining drug approvals sequentially in Australia and the Middle East.
- Keeping strategic expansion in Southeast Asia.

Lioudu Plant Equipment Investment in Lipo-AB

- Adding a new lyophilization production line and planning to launch in Q4.

In-Licensing
International New Drugs

Aligning with International Standard Therapies

- Minjuvi driving revenue growth.
- Aligning with international practices, the adjuvanted flu vaccine is now available for adults aged 50 and older.
- Expanding the vaccine portfolio with the introduction of varicella vaccine.

Cross-Border Corporate Collaborations

- Leveraging product synergies for Avastin and Rozlytrekt.
- Introducing the new anti-leukemia drug, Xpovio.

Self-manufacture
Domestic New Drugs / Generics

Sustaining R&D Momentum

- Self-manufactured the targeted drug for lung cancer, Pulmivex, has been covered by National Health Insurance.
- Self-manufactured antibiotic, Bobimixyn, has reported impressive sales.

Ensuring Resilience in Generics

- Securing a resilient supply of Gemmis.
- Cubiyo shipments scheduled to commence in Q4.

Q&A